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Differential effect of quetiapine and lithium
on functional connectivity of the striatum
in ﬁrst episode mania
Orwa Dandash1,2, Murat Yücel1,2, Rothanthi Daglas3,4, Christos Pantelis 2,5, Patrick McGorry3,4, Michael Berk 3,4,6,7,8 and
Alex Fornito1
Abstract
Mood disturbances seen in ﬁrst-episode mania (FEM) are linked to disturbed functional connectivity of the striatum.
Lithium and quetiapine are effective treatments for mania but their neurobiological effects remain largely unknown.
We conducted a single-blinded randomized controlled maintenance trial in 61 FEM patients and 30 healthy controls.
Patients were stabilized for a minimum of 2 weeks on lithium plus quetiapine then randomly assigned to either lithium
(serum level 0.6 mmol/L) or quetiapine (dosed up to 800 mg/day) treatment for 12 months. Resting-state fMRI was
acquired at baseline, 3 months (patient only) and 12 months. The effects of treatment group, time and their
interaction, on striatal functional connectivity were assessed using voxel-wise general linear modelling. At baseline,
FEM patients showed reduced connectivity in the dorsal (p= 0.05) and caudal (p= 0.008) cortico-striatal systems
when compared to healthy controls at baseline. FEM patients also showed increased connectivity in a circuit linking
the ventral striatum with the medial orbitofrontal cortex, cerebellum and thalamus (p= 0.02). Longitudinally, we found
a signiﬁcant interaction between time and treatment group, such that lithium was more rapid, compared to
quetiapine, in normalizing abnormally increased functional connectivity, as assessed at 3-month and 12-month follow-
ups. The results suggest that FEM is associated with reduced connectivity in dorsal and caudal corticostriatal systems,
as well as increased functional connectivity of ventral striatal systems. Lithium appears to act more rapidly than
quetiapine in normalizing hyperconnectivity of the ventral striatum with the cerebellum. The study was registered on
the Australian and New Zealand Clinical Trials Registry (ACTRN12607000639426). http://www.anzctr.org.au
Introduction
First-episode mania (FEM) patients can exhibit difﬁ-
culties in emotion regulation and deﬁcits in cognitive
function such as attention, response inhibition and
working memory1 that are commonly linked to the
functional integrity of neural circuits connecting pre-
frontal cortex (PFC) with subcortical and limbic struc-
tures2–5.
Key among these are the cortico-striato-thalamic (CST)
and cortico-striato-cerebellar (CSC) networks, which are
thought to mediate a broad array of cognitive, motor and
affective processes6,7. The striatum is as an important
structure in these networks, representing a key point for
integrating diverse cortical and cerebellar inputs. Broadly,
the functional organization of the striatum evolves along
dorsal-to-ventral and medial-to-lateral axes which sepa-
rate the associative striatum (head of the caudate nucleus
and dorsorostral putamen) from the motor (caudate tail
and dorsocaudal putamen) and the limbic (ventral stria-
tum/nucleus accumbens) subdivisions6,8. The striatum is
thus well-positioned to play a critical role in functions
that integrate cognitive processes with emotional drives to
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implement motor outputs—an ability that is thought to be
fundamentally disrupted in bipolar disorder9.
A popular method for studying striatal and other brain
networks is to use functional magnetic resonance imaging
(fMRI) to record coordinated, spontaneous brain
dynamics in the absence of an explicit task (the so-called
resting-state)10,11. The signal ﬂuctuations recorded with
resting-state fMRI are organized into well-deﬁned net-
works12, including speciﬁc CST and CSC systems13–15.
These networks are robust over time16,17, heritable18 and
inﬂuence task-evoked activity and behavior19,20, suggest-
ing that they represent an intrinsic and functionally
important property of brain activity21.
Several resting-state fMRI studies have found that
patients with bipolar disorder show disturbances in
coordinated brain activity—so-called functional con-
nectivity—between the striatum and other brain
areas22–24. In the largest resting-state study to date,
increased connectivity between a medial paralimbic
resting-state network, involving the ventromedial pre-
frontal cortex and the ventral striatum, with a network
thought to subserve emotion regulation and executive
function, including subgenual cingulate and insula, dis-
tinguished bipolar patients from schizophrenia patients
and healthy controls, suggesting that interactions between
cognitive and emotional networks may be speciﬁcally
disrupted in bipolar disorder24. Similarly, another analysis
found that functional connectivity between the basal
ganglia, thalamus and cortical areas implicated in cogni-
tion were the most distinguishing feature between bipolar
patients and healthy controls, achieving a classiﬁcation
accuracy of 90%25. Furthermore, altered functional con-
nectivity in the cognitive and affective subdivisions of the
striatum has been shown to differentiate manic patients
from depressed bipolar patients26. Collectively, these
ﬁndings suggest that bipolar disorder is associated with
abnormal coupling between striatal and other brain areas
involved in cognitive and emotional processes.
Most fMRI studies have included patients treated with
the mood stabilizer lithium, second-generation anti-
psychotics such as quetiapine, or adjunctive therapy22–24.
The evidence from randomized-controlled studies sug-
gests that quetiapine is an effective treatment of bipolar
mania27 and bipolar depression28, for maintenance ther-
apy29, and as an adjunct treatment to lithium, where
efﬁcacy may be greater than quetiapine monotherapy30.
However, no study to date has investigated the differential
effect of monotherapy of either of the drugs on resting-
state functional connectivity in First Episode Mania
(FEM) patients. This is mainly due to the low incidence of
FEM and the consequent difﬁculty in recruiting affected
patients31,32. In addition, previous studies have used
cross-sectional designs, which do not allow an assessment
of how treatment changes brain function over time. More
importantly, there are no randomized designs in these
cohorts.
In this study, we aimed to investigate changes in the
resting-state functional connectivity of four key regions of
the striatum, encompassing dorsal (cognitive), ventral
(affective) and caudal (motor) circuits in FEM patients
randomized to either quetiapine or lithium. Patients were
scanned at baseline, 3 months and 12 months, with a
sample of healthy controls also scanned at the baseline
and 12-month assessments. We expected that functional
connectivity of both the dorsal and ventral striatum would
be altered in patients compared to controls at baseline.
We also predicted, in light of the evidence for the clinical
efﬁcacy of both lithium and quetiapine in treating manic
patients27,29,30, that treatment with both drugs would
normalize baseline abnormalities over the follow-up
period.
Subjects and methods
Participants
Sixty-one participants with FEM were recruited via
Orygen Youth Health and Monash Health between
December 2008 and December 2013. Patients were
screened with the Structured Clinical Interview for DSM-
IV-TR by trained clinicians and were diagnosed with
mania (bipolar I disorder, schizoaffective disorder, or a
substance-induced mood disorder). Individuals presenting
with an acute manic episode with psychotic features and
who had not been previously treated for a manic episode
were stabilised on a combination of quetiapine plus
lithium in an open label manner as part of a routine care
protocol. Following provision of informed oral and writ-
ten consent, patients were randomised after remission
(2–3 months), to lithium or quetiapine monotherapy.
Patients were required to have been on a combination of
quetiapine and lithium as standard therapy for at least
1 month prior to randomisation, and to have a score of at
least 20 on the Young Mania Rating Scale (YMRS)33
during their acute manic episode. Female patients were
required to be using effective contraception if they were
sexually active and of childbearing age. Patients of 15–25
years of age, who were ﬂuent in English, had the capacity
to provide informed consent, and comply with study
procedures, were randomised to treatment allocation of
either lithium or quetiapine monotherapy. The Mel-
bourne Health and Monash Health Human Research
Ethics Committees approved the protocol in accordance
with the Helsinki Declaration.
Exclusion criteria
Patients were excluded for known or suspected clini-
cally relevant systemic medical disorder, organic mental
disease or a history of epilepsy; sensitivity or allergy to
quetiapine, lithium or any additives in the medication;
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prior use of medication with a cytochrome P450 3A4
inhibiting effect in the 14 days preceding enrolment;
inability to comply with the requirements of giving
informed consent or the treatment protocol; immediate
risk of self-harm or of harming others; pregnancy or
breastfeeding; or diabetes mellitus.
Randomisation and blinding
At the discretion of the treating team an independent
statistician generated a computerised randomisation
sequence 2–3 months following stabilisation from a FEM.
A randomisation log was established and a set of
sequentially ordered envelopes was kept in a locked ﬁling
cabinet at the Orygen Research Centre. The patients,
treating psychiatrist and case managers knew which
treatment the patient was receiving while research assis-
tants, neuropsychologists, and all individuals involved in
neuroimaging, analysis, and data management remained
blinded to this information.
Study protocol
Of the 61 recruited subjects, 31 subjects were allocated
to quetiapine treatment and 30 patients were allocated to
lithium treatment. A single researcher (RD) conducted all
clinical and diagnostic assessments. Clinical assessments
were carried out at baseline and on fortnightly intervals
for the ﬁrst month, then on a monthly basis for the fol-
lowing 2 months, and then at 3 monthly intervals there-
after concluding at the 1-month time point. These
included observer-based ratings using the YMRS33 for
manic symptoms, the Montgomery-Åsberg Depression
Rating Scale MADRS;34 for depressive symptoms, the
Brief Psychiatric Rating Scale BPRS;35; for psychotic
symptoms, and the Clinical Global Impressions scale for
use in Bipolar disorder CGI-BP;36; to determine overall
symptom severity. Control subjects underwent MRI
scanning at baseline and at the 12-month time points
whereas FEM patients were scanned at baseline, 3 and 12-
month time points to assess response to treatment.
MRI data acquisition
A single scanner at the Murdoch Children’s Research
Institute at Royal Children’s Hospital in Melbourne,
Australia (3 T Siemens Trio Tim, 32 channel head coil)
was used to acquire high-resolution structural T1
Magnetization-Prepared RApid Gradient-Echo
(MPRAGE)37 scans for each subject. Image acquisition
parameters at every time-point were as follows:
192 sagittal slices with a nominal 1mm3 voxel size,
256mm × 232mm Field-of-View (FoV) and a matrix size
of 256 × 192 or 512 × 384 pixel resolution (the latter had
0.5 × 0.5 mm in-plane resolution), 2000ms repetition time
(TR) and 2.24 ms echo time (TE). T2*-weighted echo-
planar images were acquired under eyes-closed resting-
state conditions. Subsequent participant debrieﬁng
ensured that no participants fell asleep during the scan.
Functional MRI was acquired using a T2*-weighted
sequence with 3.3 × 3.3 × 3.0 mm voxel size, a TR of
2400 ms, TE of 30ms, ﬂip angle of 90° in 64 × 64 matrix
size and 384mm FoV. A total of 307 volumes comprising
36 slices each were acquired.
Imaging preprocessing
An established procedure was used to characterize
corticostriatal functional connectivity in relation to four
seed regions located in ventral and dorsal areas of the
caudate nucleus and putamen per hemisphere13,38,39.
Seeds were deﬁned in both hemispheres as 3.5 mm radial
spheres at the following stereotaxic coordinates: dorsal
caudate (x= ±13, y= 15, z= 9); ventral striatum/nucleus
accumbens (x= ±9, y= 9, z=−8); dorsal-caudal puta-
men (x= ±28, y= 1, z= 3) ventral-rostral putamen (x=
± 20, y= 12, z=−3). A secondary seed-based analysis was
conducted in which two 3.5 mm spherical seeds were
placed in the right and left visual cortex as described
elsewhere40. Image preprocessing was performed using
statistical parametric mapping software (SPM8) and
included slice-timing correction, motion correction via
afﬁne transformation to the ﬁrst image and coregistration
of functional images with subjects’ anatomical scans,
which were concurrently normalized to the SPM-T1
template. The resulting transformation matrix was
applied to the functional data to achieve accurate spatial
normalization across individuals. The anatomical scans
were also segmented using a uniﬁed normalization and
segmentation approach41.
White matter and CSF were generated by thresholding
the corresponding tissue images segmented from the
T1 scan at 99 and 50% tissue probability, respectively. Any
overlap with the grey matter mask (thresholded at 1%)
was removed by image subtraction. Voxelwise time series
were extracted from the white matter and CSF masks and
subjected to the aCompCor method42, in which voxelwise
time course from each tissue mask were subjected to
separate principal component analyses. The ﬁrst ﬁve
components from each mask were retained as nuisance
regressors modelling physiological noise and head motion
effects. All data were linearly detrended and a linear
regression model that included these ten component
signals, together with the six head motion parameters
(three rotation, three translation) estimated during the
head motion correction procedure, and the ﬁrst-order
derivatives of all sixteen signals were then ﬁtted on a
voxelwise basis. This approach has been shown to suc-
cessfully control for head motion and physiological noise
in fMRI data43. The noise-corrected data were then band
pass ﬁltered (0.008 < f < 0.08) and spatially smoothed with
a Gaussian ﬁlter (8 mm full-width at half-maximum). All
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image sequences were routinely inspected for potential
normalization artifacts. Mean time series were extracted
from each striatal seed in both hemispheres. The data of
one patient at baseline was excluded due to excessive head
motion (>3 mm translation and >3° rotation). This
resulted in a ﬁnal sample of 30 control subjects, and 40
patients at baseline. The ﬁnal sample for both treatment
groups at 3 months (denoted m3) was 13 subjects in the
quetiapine group and 16 subjects in the lithium group. At
12 months (denoted m12), there was 20 subjects in the
control group, 12 subjects in the quetiapine group and
14 subjects in the lithium group.
First-level, within-subjects analysis
For each participant, functional connectivity maps were
estimated using general linear models (GLM) as imple-
mented in SPM8. Time courses extracted from each
striatal sub-region were entered into a single GLM that
included all striatal seeds as covariates of interest in a
whole-brain regression analysis. Contrast images were
generated for each participant by estimating the regres-
sion coefﬁcient between all brain voxels and each region’s
time-series for left and right hemisphere seeds.
Second-level, between-condition analysis
Separate second-level models were used to test for (1)
baseline disease-related changes in corticostriatal effects,
and (2) the longitudinal effects of treatment. For the ﬁrst
analysis, separate models were used to test for group
differences in the functional connectivity of each of the
four seed regions, with group (patient, control) and
hemisphere (left and right) as covariates of interest and
age and gender as nuisance covariates. Between-group
statistical maps were thresholded at a P < .001 uncor-
rected and subjected to cluster-based correction for
multiple comparison at P < .05 determined by a Monte
Carlo simulation test44 based on the recently amended
3dClustSim algorithm45.
The longitudinal effect of treatment was characterized
using a 3 × 2 random-effects ﬂexible factorial design with
group (control, quetiapine and lithium) and time (base-
line, m12) as factors and age and gender as nuisance
covariates. A separate 2 × 3 random-effect design was
used to characterize the effect of treatment at m3 in the
patients groups only. Longitudinal effects were mapped by
masking the F-contrast for the group × time interaction
with the statistical map of the baseline differences
between patients and controls to ensure that the inﬂuence
of treatment was characterized in brain regions that are
(1) functionally connected to the striatum; and (2) of
primary pathophysiological relevance to the disorder.
Interaction effects within this mask that survived a
threshold of P < .05 small volume-corrected, were deemed
signiﬁcant.
Clinical associations
Change from baseline scores were computed for the
BPRS total (ΔBPRStot12), MADRS (ΔMADRS12), CGI-
BP severity of depression (ΔCGI-BPsevDepres12), and
CGI-BP overall severity of bipolar (ΔCGI-BPsevBP12) by
subtracting m12 clinical scores from baseline scores46.
Results
Demographics and clinical outcomes
Of the 61 recruited subjects, 11 in the quetiapine
treatment group and 9 in the lithium treatment group
were excluded at or before randomization took place for
the following reasons; relapse at baseline or prior to
commencement of monotherapy (n= 5); self-ceasing of
all medications (n= 3); non-stability on monotherapy (n
= 2); preference for the non-randomized medication (n=
3); clinician withdrawal due to side effects (n= 2) and
treatment disengagement (n= 4) (Fig. 1). Twenty-one
patients were allocated to quetiapine treatment and
20 subjects were allocated to lithium. Two additional
subjects were excluded at baseline; one subject due to
never being on monotherapy and one subject due to non-
compliance to randomized medication (see CONSORT
ﬂowchart in Supplement for more information) rendering
a ﬁnal sample of 19 subjects in the quetiapine group and
20 subjects in the lithium group. Three patients in the
quetiapine group and four in the lithium group dis-
continued after their baseline participation.
Treatment groups were matched for age, gender,
handedness and IQ but only matched for age and hand-
edness with the control group (Table 1). Baseline clinical
scores did not differ between the two treatment groups
(patients assigned to lithium or quetiapine), indicating
that stabilization was successful. As reported in refs 46,47,
the lithium group demonstrated signiﬁcant improvement
compared to quetiapine after 12 months on rating scales
of depression, psychosis, and mood instability.
Baseline effects of disease
At baseline, all patients (i.e., both treatment groups),
when compared to controls, demonstrated increased
functional connectivity in the putative affective corticos-
triatal network, linking the ventral striatum (nucleus
accumbens) and the ventromedial orbitofrontal cortex
(vmOFC), cerebellum, and the thalamus in the right
hemisphere (Fig. 1a). Patients showed reduced functional
connectivity between the dorsal caudate and DLPFC in
the right hemisphere (Fig. 1; Table 2). Patients also
showed reduced connectivity between the dorsocaudal
putamen and the premotor area, and between the same
putamen seed and the caudate nucleus bilaterally (Fig. 1;
Table 2). There was no signiﬁcant difference in functional
connectivity between the two treatment groups at
baseline.
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Fig. 1 Z-score statistical map of signiﬁcant baseline comparison in functional connectivity between control subjects and ﬁrst-episode
mania patients collapsed across both treatment groups; quetiapine and lithium. DC dorsal caudate nucleus, DP dorsal putamen, VS ventral
striatum including the nucleus accumbens. R right hemisphere. Insets show results overlaid on glass brain. Results are displayed at P < 0.05 (FWE
cluster corrected). For more information see Supplementary Materials
Table 1 Demographics of treatment groups and control subjects
Demographics Control N= 30 Quetiapine (N= 19) Lithium (N= 20) Statistics
N % N % N % χ2 P
Gender
Male 12 40 14 70 16 84 9.87 .007
Female 18 60 5 30 4 16
Handednessa
Right-handed 26 93 15 83 19 95 3.64 .162
Left-handed 2 7 3 17 0 0
Age Mean s.d. Mean s.d. Mean s.d. F P
21.40 2.46 21.47 2.14 21.45 2.31 0.145 .88
Premorbid IQ (WTAR)b 105.43 10.82 92.89 13.80 96.71 13.89 11.37 .001
Diagnosis
Bipolar disorder — — 19 100 17 85 1.89 1.17
Schizoaffective disorder — — 1 5 1 5 0.04 1.84
Substance-induced Mania — — 1 5 1 5 0.08 1.80
aData for two subjects in the control group and one subject in the quetiapine and the lithium group were missing.
bWTAR: Wechsler Test of Adult Reading (UK scaled score)
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Longitudinal effects of treatment
A signiﬁcant group × time interaction was identiﬁed for
functional connectivity between the ventral striatum and
right cerebellum (Fig. 2 and Table 2). Post-hoc t-tests
showed that both treatment groups showed increased
connectivity when compared to control subjects at base-
line (quetiapine t1,68= 3.0, P= .001 cluster-corrected;
lithium t1,68= 3.6, P= .001 cluster-corrected). At m3,
patients treated with lithium showed reduced functional
connectivity compared to those treated with quetiapine
(t1,27= 2.0, P < .05 svc). After m12, the two treatment
groups did not differ in their connectivity strength,
although both were signiﬁcantly higher than controls
(Fig. 2; quetiapine t1,30= 1.6, P < .05 svc; lithium
t1,34= 1.75, P < .05 svc).
Clinical associations
In an exploratory analysis, we next examined whether
the treatment-related changes in functional connectivity
were related to symptom improvement. We extracted
estimate of functional connectivity from the cerebellar
region showing a signiﬁcant group × time interaction and
correlated these estimates with measures of symptom
change. In the lithium group, functional connectivity
between the ventral striatum and cerebellum was asso-
ciated with symptom improvement on the following
scales in the lithium group: ΔCGI-BPsevDepres12 (r=
0.51, n= 14, P= .022) and ΔCGI-BPsevBP12 (r= 0.51, n
= 14, P= .021). However, none of these associations
survived full Bonferroni correction for multiple compar-
isons (α= 0.0125).
An additional exploratory association analysis was
conducted in which baseline functional connectivity
estimates, outside of the brain regions that represent
between-group differences (Fig. 1), were examined to see
whether they predict symptom improvement after
12 months. Symptom scores were entered as variables of
interest in a voxel-wise whole-brain regression analysis
while controlling for age and gender. Baseline functional
connectivity predicted improvement in symptom scores
in both treatment groups after 12 months (Supplementary
Figures 2 and 3). Speciﬁcally, connectivity of the ventral
striatum with the right temporal cortex predicted
improvement on BPRS (r= 0.83, n= 14, P= .012 FWE
Table 2 Brain regions demonstrating signiﬁcant between-group differences in functional connectivity (P < 0.05; FWE
cluster corrected) and group × time interactions (P < 0.05; small-volume corrected)
Main Effect Anatomical Region Hemisphere MNI Peak Coordinates (x,y,z) Z-score Voxels
DC DLPFC Right 30,54,34 4.16 156
PTdc Caudate Nucleus Right 18,6,22 4.53 632
Putamen Globus Pallidus Left −26,−2,−2 4.28 167
Caudate Nucleus Left −22,−2,20 4.27 1043
Premotor Cortex Left −18,12,56 3.56 183
Premotor Cortex Right 24,14,46 3.52 120
VS mOFC Right 4,0,−18 4.59 225
Thalamus Right 16,−12,6 3.94 140
Cerebellum Left −14,−48,−14 3.93 120
Cerebellum Right 28,−50,−28 3.91 134
Group x Time Interaction
VS Cerebellum Right 32,−48,−28 3.73 73
DC dorsal caudate, PTdc dorsocaudal Putamen, VS ventral striatum.
Fig. 2 Group × time interaction in ventral striatum (VS) functional
connectivity with the Right cerebellum. *Signiﬁcant at P < .05 small
volume corrected. Error bars represent standard error of the mean. See
Results section for more information on between group comparisons
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Cluster corrected) while connectivity between the ventral
striatum and the right middle frontal gyrus predicted
improvement on MADRS scores (r= 0.86, n= 14, P
= .001 FWE Cluster corrected) in the lithium group
(Supplementary Figure 1). In the quetiapine group, con-
nectivity of the ventral striatum and the ACC predicted
improvement on BPRS scores (r= 0.68, n= 12, P= .001
FWE Cluster corrected) (Supplementary Figure 2). These
effects survived full Bonferroni correction for multiple
comparisons (α= 0.0125).
There was no clinical association with the connectivity
of the visual cortex as suggested by the secondary analysis
(Supplementary Figure 1). This latter analysis supports
the speciﬁcity of the results to ventral striatum
connectivity.
Discussion
FEM patients showed reduced functional connectivity
of dorsal cortico-striatal circuitry, coupled with abnor-
mally increased functional connectivity of a ventral CSC
network. The connectivity abnormalities normalized to a
similar extent over the 12-month period of this study in
patients treated with either lithium or quetiapine, but the
changes occurred earlier in the lithium-treated group,
being apparent at 3 months. These ﬁndings suggest that
the therapeutic effect of quetiapine in FEM may be
delayed relative to lithium, at least with respect to nor-
malizing functional connectivity of the ventral striatum
with the cerebellum. We note however, that the
abnormalities did not completely normalize, with residual
differences between the two patient groups and healthy
controls still apparent at 12 months.
Paralleling its traditional role in controlling movement,
the cerebellum plays an important role in modulating
emotions48,49. The cerebellum sends monosynaptic pro-
jections to the basal ganglia as well as other limbic sub-
cortical structures including the hippocampus and the
amygdala7,48. Lesions to the posterior and vermal cere-
bellum lead to disinhibition and inappropriate behavior, a
characteristic feature of mania50. Moreover, the cere-
bellum commonly appears as one of the most activated
brain regions during emotion appraisal51,52 and a reduc-
tion in cerebellar volume is associated with the number of
affective episodes, including manic and hypomanic epi-
sodes, in bipolar patients53.
In a recent volumetric study of this cohort, we found
reduced cerebellar volume in FEM patients at baseline,
when compared to control subjects, in the same region
that shows increased connectivity with the ventral stria-
tum54. These ﬁndings further support the role of the
cerebellum in mediating affect and suggest that increased
functional connectivity in the limbic circuit may be rela-
ted to the structural deﬁcit in the cerebellum. One
hypothesis is that increased functional connectivity with
the ventral striatum represents a compensatory response
to a structural lesion in this area, although testing this
hypothesis would require a thorough behavioural assess-
ment55. Unlike our previous study, which found that
cerebellar volume was not responsive to treatment54, we
report here that medication improves striatocerebellar
connectivity, suggesting that functional measures may be
more sensitive to the effects of pharmacotherapy (Fig. 2).
Changes in functional connectivity of the ventral stria-
tum were accompanied by improvement in symptoms
after 12 months in the lithium group only. This ﬁnding
was further cemented by the secondary exploratory ana-
lysis in which baseline functional connectivity of the
ventral striatum predicted improvement in depressive and
general psychiatric symptoms in the lithium group but
only general psychiatric symptoms in the quetiapine
group (Supplementary Figures 2–3). As noted in another
study of this sample46, the ﬁndings favour lithium over
quetiapine and point to a recurrent theme that implicates
the ventral striatum as a major culprit in mediating manic
symptoms and potentially the pharmacological effect of
treatment.
The increased ventral striatal connectivity with the
vmOFC and medial thalamus observed in patients at
baseline is another indicator that the canonical ventral
(limbic) corticostriatal circuit is compromised in mania.
The vmOFC coordinates and integrates somatosensory
information, including emotion, in decision-making and
plays a role in assigning positive value to stimuli56. Bipolar
patients and their unaffected ﬁrst degree relatives illicit
similar responses in the vmOFC even in the absence of
rewarding stimuli, and have previously been shown to
exhibit alterations in striatothalamic functional con-
nectivity akin to their affected relatives24,57. These ﬁnd-
ings suggest that functional connectivity disturbances in
ventral striatum connectivity could be a trait marker for
the illness. This notion is further supported by the
observation that increased connectivity of the ventral
striatum was present at baseline in both treatment groups
after the stabilization phase. In other words, the dis-
turbance may not be related to the onset of the illness
per se but to other biological factors closer to the etiology
of the illness58.
Notably, FEM patients also showed reduced functional
connectivity in the dorsal corticostriatal system at base-
line. We have observed a similar gradient of dorsal-to-
ventral, hypoconnectivity-to-hyperconnectivity in a sepa-
rate sample of patients with ﬁrst episode schizophrenia-
like psychosis and their unaffected relatives38. We have
also found hypoconnectivity of the dorsal system in peo-
ple with an at-risk mental state for psychosis59. Most
patients in this study had experienced an episode of
psychosis, suggesting that dorsal corticostriatal hypo-
connectivity may be a risk marker for psychosis that
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transcends traditional diagnostic boundaries. Further
work examining how corticostriatal connectivity covaries
with speciﬁc symptoms or syndromes across diagnoses
will be required to test this hypothesis.
Strengths of the study include the relative homogeneity
of the sample, the selection of a ﬁrst episode cohort,
randomized assignment to treatment groups and a long-
itudinal design. The study included 10% of individuals
with schizoaffective disorder and substance-induced
mania, which may have inﬂuenced the results, poten-
tially favoring quetiapine given its efﬁcacy in treating
schizoaffective disorders60. Nonetheless, the number of
subjects with either disorder was matched in the two
treatment groups, thus reducing the variability con-
tributed by these diagnoses and rendering the study more
representative of FEM patient samples in Western socie-
ties22,24. Limitations include the relatively modest sample,
which is expected for such a difﬁcult to recruit and engage
population. Multi-site investigations may prove useful in
establishing the samples required for more robust multi-
variate methods to assess the utility of striatal functional
connectivity in predicting treatment effects.
Acknowledgements
This study was supported by an unrestricted grant from Astra Zeneca. The
funding organization had no role in the design and conduct of the study;
collection, management, analysis, and interpretation of the data; preparation,
review, or approval of the manuscript; and decision to submit the manuscript
for publication. MB was supported by a NHMRC Senior Principal Research
Fellowship 1059660. C.P. was supported by a NHMRC Senior Principal Research
Fellowship (ID: 628386 & 1105825). P.M. was supported by a NHMRC SPR
fellowship. A.F. was supported by the Australian Research Council (ID:
FT130100589) and NHMRC (ID: 1050504). M.Y. was supported by a National
Health and Medical Research Council Fellowship (ID: 1117188) and the David
Winston Turner Endowment Fund.
Author details
1Brain & Mental Health Laboratory, School of Psychological Sciences & Monash
Institute of Cognitive and Clinical Neurosciences, Monash University, Clayton,
VIC 3168, Australia. 2Melbourne Neuropsychiatry Centre, Department of
Psychiatry, The University of Melbourne and Melbourne Health, Carlton South,
VIC, Australia. 3Orygen, The National Centre of Excellence in Youth Mental
Health, 35 Poplar Road, Parkville, VIC 3052, Australia. 4Centre for Youth Mental
Health, University of Melbourne, 35 Poplar Road, Parkville, VIC 3052, Australia.
5Florey Institute for Neuroscience and Mental Health, Kenneth Myer Building,
Royal Parade, Parkville VIC Australia. 6IMPACT Strategic Research Centre, School
of Medicine, Deakin University, Geelong VIC 3220, Australia. 7Orygen Youth
Health Clinical Program, 35 Poplar Road, Parkville VIC 3052, Australia. 8Barwon
Health and the Geelong Clinic, Swanston Centre, Geelong, VIC 3220, Australia
Conﬂict of interest
M.B. has received Grant/Research Support from Bristol Myers Squibb, Eli Lilly,
Glaxo SmithKline, Meat and Livestock Board, Organon, Novartis, Mayne
Pharma, Servier and Woolworths, has been a speaker for Astra Zeneca, Bristol
Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck, Merck, Pﬁzer,
Sanoﬁ Synthelabo, Servier, Solvay and Wyeth, and served as a consultant to
Astra Zeneca, Bioadvantex, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline,
Janssen Cilag, Lundbeck Merck and Servier. C.P. has participated on Advisory
Boards for Janssen-Cilag, Astra-Zeneca, Lundbeck, and Servier and has received
honoraria for talks presented at educational meetings organised by Astra-
Zeneca, Janssen-Cilag, Eli-Lilly, Pﬁzer, Lundbeck and Shire. P.M. has received
investigator initiated research grants from Astra Zeneca, Janssen Cilag, Eli Lilly,
and BMS. He has received honoraria for educational events from Janssen Cilag,
Eli Lilly, BMS, Astra Zeneca, Pﬁzer and Lundbeck.
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Supplementary Information accompanies this paper at (https://doi.org/
10.1038/s41398-018-0108-8).
Received: 15 April 2017 Revised: 28 October 2017 Accepted: 30 December
2017
References
1. Daglas, R. et al. Cognitive impairment in ﬁrst-episode mania: a systematic
review of the evidence in the acute and remission phases of the illness. Int. J.
Bipolar Disord. 3, 9 (2015).
2. Vargas, C., Lopez-Jaramillo, C. & Vieta, E. A systematic literature review of
resting state network--functional MRI in bipolar disorder. J. Affect. Disord. 150,
727–735 (2013).
3. Marchand, W. R. & Yurgelun-Todd, D. Striatal structure and function in mood
disorders: a comprehensive review. Bipolar Disord. 12, 764–785 (2010).
4. Price, J. L., Carmichael, S. T. & Drevets, W. C. Networks related to the orbital and
medial prefrontal cortex; a substrate for emotional behavior? Prog. Brain. Res.
107, 523–536 (1996).
5. Price, J. L. & Drevets, W. C. Neural circuits underlying the pathophysiology of
mood disorders. Trends Cogn. Sci. 16, 61–71 (2012).
6. Alexander, G. E., DeLong, M. R. & Strick, P. L. Parallel organization of functionally
segregated circuits linking basal ganglia and cortex. Annu. Rev. Neurosci. 9,
357–381 (1986).
7. Bostan, A. C., Dum, R. P. & Strick, P. L. The basal ganglia communicate with the
cerebellum. Proc. Natl. Acad. Sci. USA 107, 8452–8456 (2010).
8. Haber, S. N. The primate basal ganglia: parallel and integrative networks. J.
Chem. Neuroanat. 26, 317–330 (2003).
9. McKenna, B. S. & Eyler, L. T. Overlapping prefrontal systems involved in cog-
nitive and emotional processing in euthymic bipolar disorder and following
sleep deprivation: a review of functional neuroimaging studies. Clin. Psychol.
Rev. 32, 650–663 (2012).
10. Biswal, B., Yetkin, F. Z., Haughton, V. M. & Hyde, J. S. Functional connectivity in
the motor cortex of resting human brain using echo-planar MRI. Magn. Reson.
Med. 34, 537–541 (1995).
11. Fornito, A. & Bullmore, E. T. What can spontaneous ﬂuctuations of the blood
oxygenation-level-dependent signal tell us about psychiatric disorders? Curr.
Opin. Psychiatr. 23, 239–249 (2010).
12. Smith, S. M. et al. Correspondence of the brain’s functional architecture during
activation and rest. Proc. Natl. Acad. Sci. USA 106, 13040–13045 (2009).
13. Di Martino, A. et al. Functional connectivity of human striatum: a resting state
FMRI study. Cereb. Cortex. 18, 2735–2747 (2008).
14. Harrison, B. J. et al. Altered corticostriatal functional connectivity in obsessive-
compulsive disorder. Arch. Gen. Psychiatry 66, 1189–1200 (2009).
15. Bernard, J. A. et al. Resting state cortico-cerebellar functional connectivity
networks: a comparison of anatomical and self-organizing map approaches.
Front. Neuroanat. 6, 31 (2012).
16. Damoiseaux, J. S. et al. Consistent resting-state networks across healthy sub-
jects. Proc. Natl. Acad. Sci. USA 103, 13848–13853 (2006).
17. Shehzad, Z. et al. The resting brain: unconstrained yet reliable. Cereb. Cortex.
19, 2209–2229 (2009).
18. Fornito, A. et al. Genetic inﬂuences on cost-efﬁcient organization of human
cortical functional networks. J. Neurosci. 31, 3261–3270 (2011).
19. Fox, M. D., Snyder, A. Z., Vincent, J. L. & Raichle, M. E. Intrinsic ﬂuctuations within
cortical systems account for intertrial variability in human behavior. Neuron 56,
171–184 (2007).
20. Fox, M. D., Snyder, A. Z., Zacks, J. M. & Raichle, M. E. Coherent spontaneous
activity accounts for trial-to-trial variability in human evoked brain responses.
Nat. Neurosci. 9, 23–25 (2006).
21. Fox, M. D. & Raichle, M. E. Spontaneous ﬂuctuations in brain activity observed
with functional magnetic resonance imaging. Nat. Rev. Neurosci. 8, 700–711
(2007).
22. Anticevic, A. et al. Archival report: global prefrontal and fronto-amygdala
dysconnectivity in bipolar I disorder with psychosis history. Biol. Psychiatry 73,
565–573 (2013).
Dandash et al. Translational Psychiatry  (2018) 8:59 Page 8 of 9
23. Lois, G., Linke, J. & Wessa, M. Altered functional connectivity between emo-
tional and cognitive resting state networks in euthymic bipolar I disorder
patients. PLoS. One. 9, e107829 (2014).
24. Meda, S. A. et al. Differences in resting-state functional magnetic resonance
imaging functional network connectivity between schizophrenia and psy-
chotic bipolar probands and their unaffected ﬁrst-degree relatives. Biol. Psy-
chiatry 71, 881–889 (2012).
25. Teng, S. et al. Classiﬁcation of bipolar disorder using basal-ganglia-related
functional connectivity in the resting state. Conf. Proc. IEEE Eng. Med. Biol. Soc.
2013, 1057–1060 (2013).
26. Altinay, M. I., Hulvershorn, L. A., Karne, H., Beall, E. B. SpringerAmpamp; Anand,
A. Differential resting-state functional connectivity of striatal subregions in
bipolar depression and hypomania. Brain Connect. 6, 255–265 (2016).
27. McIntyre, R. S., Brecher, M., Paulsson, B., Huizar, K. & Mullen, J. Quetiapine or
haloperidol as monotherapy for bipolar mania—a 12-week, double-blind,
randomised, parallel-group, placebo-controlled trial. Eur. Neuropsycho-
pharmacol. 15, 573–585 (2005).
28. Calabrese, J. R. et al. A randomized, double-blind, placebo-controlled trial of
quetiapine in the treatment of bipolar I or II depression. Am. J. Psychiatry 162,
1351–1360 (2005).
29. Suppes, T. et al. Maintenance treatment for patients with bipolar I disorder:
results from a north american study of quetiapine in combination with lithium
or divalproex (trial 127). Am. J. Psychiatry 166, 476–488 (2009).
30. Sachs, G. et al. Quetiapine with lithium or divalproex for the treatment of
bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar
Disord. 6, 213–223 (2004).
31. Chai, X. J. et al. Abnormal medial prefrontal cortex resting-state connectivity in
bipolar disorder and schizophrenia. Neuropsychopharmacology 36, 2009–2017
(2011).
32. Ongur, D. et al. Default mode network abnormalities in bipolar disorder and
schizophrenia. Psychiatry Res. 183, 59–68 (2010).
33. Young, R. C., Biggs, J. T., Ziegler, V. E. & Meyer, D. A. A rating scale for mania:
reliability, validity and sensitivity. Br. J. Psychiatry 133, 429–435 (1978).
34. Montgomery, S. A. & Asberg, M. A new depression scale designed to be
sensitive to change. Br. J. Psychiatry.: J. Ment. Sci. 134, 382–389 (1979).
35. Ventura, J. L. D., Nuechterlein, K. H., Lieberman, R. P., Green, M. & Shaner, A. Brief
Psychiatric Ratings Scale (BPRS) Expanded Version (4.0) scales, anchor points
and administration manual. Int. J. Methods Psychiatr. Res. 3, 227–243 (1993).
36. Spearing, M. K., Post, R. M., Leverich, G. S., Brandt, D. & Nolen, W. Modiﬁcation
of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the
CGI-BP. Psychiatry Res. 73, 159–171 (1997).
37. Brant-Zawadzki, M., Gillan, G. D. & Nitz, W. R. MP RAGE: a three-dimensional, T1-
weighted, gradient-echo sequence--initial experience in the brain. Radiology
182, 769–775 (1992).
38. Fornito, A. et al Functional dysconnectivity of corticostriatal circuitry as a risk
phenotype for psychosis. JAMA Psychiatry 70, 1143–1151 (2013).
39. Dandash, O. et al. Altered striatal functional connectivity in subjects with an at-
risk mental state for psychosis. Schizophr. Bull. 40, 904–913 (2013).
40. Burton, H., Snyder, A. Z. & Raichle, M. E. Resting state functional connectivity in
early blind humans. Front. Syst. Neurosci. 8, 51 (2014).
41. Ashburner, J. & Friston, K. J. Uniﬁed segmentation. Neuroimage 26, 839–851
(2005).
42. Behzadi, Y., Restom, K., Liau, J. & Liu, T. T. A component based noise correction
method (CompCor) for BOLD and perfusion based fMRI. Neuroimage 37,
90–101 (2007).
43. Muschelli, J. et al. Reduction of motion-related artifacts in resting state fMRI
using aCompCor. Neuroimage 96, 22–35 (2014).
44. Forman, S. D. et al. Improved assessment of signiﬁcant activation in functional
magnetic resonance imaging (fMRI): use of a cluster-size threshold. Magn.
Reson. Med. 33, 636–647 (1995).
45. Cox, R. W., Chen, G., Glen, D. R., Reynolds, R. C. & Taylor, P. A. FMRI Clustering in
AFNI: False-Positive Rates Redux. Brain Connect 7, 152–71 (2017).
46. Berk, M. et al. Quetiapine v. lithium in the maintenance phase following a ﬁrst
episode of mania: randomised controlled trial. Br. J. Psychiatry 210, 413–421
(2017).
47. Berk, M. et al. Neuroprotection after a ﬁrst episode of mania: a randomized
controlled maintenance trial comparing the effects of lithium and quetiapine
on grey and white matter volume. Transl. Psychiatry 7, e1041 (2017).
48. Schutter, D. J. & van Honk, J. The cerebellum on the rise in human emotion.
Cerebellum 4, 290–294 (2005).
49. Strick, P. L., Dum, R. P. & Fiez, J. A. Cerebellum and nonmotor function. Annu.
Rev. Neurosci. 32, 413–434 (2009).
50. Schmahmann, J. D. & Sherman, J. C. The cerebellar cognitive affective syn-
drome. Brain 121, 561–579 (1998). Pt 4.
51. Habel, U., Klein, M., Kellermann, T., Shah, N. J. & Schneider, F. Same or different?
Neural correlates of happy and sad mood in healthy males. Neuroimage 26,
206–214 (2005).
52. Damasio, A. R. et al. Subcortical and cortical brain activity during the feeling of
self-generated emotions. Nat. Neurosci. 3, 1049–1056 (2000).
53. Monkul, E. S. et al. MRI study of the cerebellum in young bipolar patients. Prog.
Neuropsychopharmacol. Biol. Psychiatry 32, 613–619 (2008).
54. Berk, M. et al. Neuroprotection after a ﬁrst episode of mania: a randomized
controlled maintenance trial comparing the effects of lithium and quetiapine
on grey and white matter volume. Transl. Psychiatry 7, e1011 (2017).
55. Fornito, A., Zalesky, A. & Breakspear, M. The connectomics of brain disorders.
Nat. Rev. Neurosci. 16, 159–172 (2015).
56. Kringelbach, M. L. The human orbitofrontal cortex: linking reward to hedonic
experience. Nat. Rev. Neurosci. 6, 691–702 (2005).
57. Lui, S. et al. Resting-state brain function in schizophrenia and psychotic bipolar
probands and their ﬁrst-degree relatives. Psychol. Med. 45, 97–108 (2015).
58. Gottesman, I. I. & Gould, T. D. The endophenotype concept in psychiatry:
etymology and strategic intentions. Am. J. Psychiatry 160, 636–645 (2003).
59. Dandash, O. et al. Altered striatal functional connectivity in subjects with an at-
risk mental state for psychosis. Schizophr. Bull. 40, 904–913 (2014).
60. Riedel, M. et al. Quetiapine in the treatment of schizophrenia and related
disorders. Neuropsychiatr. Dis. Treat. 3, 219–235 (2007).
Dandash et al. Translational Psychiatry  (2018) 8:59 Page 9 of 9
